Burning Cash Isn’t the Problem. Burning Alignment Is. Every biotech founder fears the day the cash runs out. You track the burn rate. You watch the runway shrink. You delay hires. You negotiate term sheets from a place of panic. But here’s what most founders miss. 👉 Cash isn’t your biggest problem. Misalignment is. Not the obvious kind either. We’re not talking about personality clashes or investor drama. 👉 We’re talking about the type of quiet misalignment that appears to
High-content screening (HCS) has become a cornerstone in GPCR and phenotypic drug discovery, enabling researchers to quantify cellular responses with spatial, temporal, and mechanistic depth.
For GPCR-focused programs, the ability to visualize receptor localization, internalization kinetics, and ligand interactions in intact cells offers advantages that extend far beyond traditional biochemical or radioligand assays.
Yet, despite remarkable progress, HCS workflows rema
